P5248
依替膦酸钠 二钠 水合物
≥97% (NMR), solid
别名:
Dihydrogen (1-hydroxyethylidene)bisphosphonate disodium hydrate
登录 查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C2H6Na2O7P2 · xH2O
化学文摘社编号:
分子量:
249.99 (anhydrous basis)
EC 号:
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
质量水平
方案
≥97% (NMR)
表单
solid
颜色
white
mp
>300 °C
溶解性
H2O: ≥10 mg/mL
储存温度
2-8°C
SMILES字符串
[Na+].[Na+].CC(O)(P(O)([O-])=O)P(O)([O-])=O
InChI
1S/C2H8O7P2.2Na/c1-2(3,10(4,5)6)11(7,8)9;;/h3H,1H3,(H2,4,5,6)(H2,7,8,9);;/q;2*+1/p-2
InChI key
GWBBVOVXJZATQQ-UHFFFAOYSA-L
相关类别
应用
Etidronate disodium hydrate has been used in the synthesis of bisphosphonate derivatives of adenosine triphosphate (ATP)by T4 RNA ligase. It has also been sued to inhibit human farnesyl diphosphate synthase (FDPS).
生化/生理作用
Bisphosphonate antiresorptive agent. Less potent inhibitor of farnesyl diphosphate synthase (IC50 = 80 μM) as compared to the nitrogen containing bisphosphonates
Etidronate helps to guard chronic ocular hypertension prompted retinal oxidative stress. It stimulates the development of retinal ganglion cells through insulin-like growth factor 1 (IGF-1) signaling pathway. It may possess neuroprotective effects in in vivo and in vitro rat model of glaucoma. Etidronate belongs to bisphosphonates.
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
Etidronate protects chronic ocular hypertension induced retinal oxidative stress and promotes retinal ganglion cells growth through IGF-1 signaling pathway
Su J and Huang M
European Journal of Pharmacology, 841, 75-81 (2018)
Isoprenoids increase bovine endometrial stromal cell tolerance to the cholesterol-dependent cytolysin from Trueperella pyogenes
Griffin S, et al.
Biology of Reproduction (2018)
Synthesis of bisphosphonate derivatives of ATP by T4 RNA ligase
Sillero M A G, et al.
Febs Letters, 580(24), 5723-5727 (2006)
Nicole C Ferko et al.
Managed care (Langhorne, Pa.), 21(11), 44-52 (2012-12-15)
Because of rising drug expenditures, cost considerations have become essential, necessitating the requirement for cost-effectiveness analyses for managed care organizations (MCOs). The study objective is to examine the impact of various drug-cost components, in addition to wholesale acquisition cost (WAC)
M R McClung et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 24(1), 301-310 (2012-10-20)
Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持